Search results for: 'analyzer'

The global pharmaceutical industry is witnessing dynamic trends following the coronavirus pandemic and is adapting to new challenges and opportunities. This study analyzes the 2021 highlights in the global pharmaceutical industry and provides forecasts for the next year and beyond. It addresses the impact of innovative modalities, technologies, ...

With this research service, Frost & Sullivan’s Healthcare and Life Sciences team provides critical insights into the European Union and UK COVID-19 vaccine and therapeutics market. The report analyzes COVID-19 vaccines and therapeutics in development and delves into supply chain considerations and requirements to manage distribution. Importantly, t...

As cell and gene therapy (CGT) moves from ultra-rare indications to more common indications, manufacturing capabilities will have to expand to support the commercial requirements of these diseases. Contract research organizations (CROs) can play a critical role in long-term genetic analysis and monitor safety and efficacy up to 15 years after treat...

The increasing disposable incomes in developing countries have contributed to a sedentary lifestyle worldwide. The advent of food delivery apps has also increased accessibility to various culinary delights. These factors have contributed mainly to obesity and other lifestyle diseases. People with a body mass index (BMI) of more than or equal to...

15 Oct 2024  |  Global  |  Technology Research

Emerging Non-opioid Treatments for Pain Management

Advances in Non-opioid Therapies for Neuropathic, Migraine, and Cancer Pain Management Unlock New Growth Opportunities

Infographics

×

The analysis explores cutting-edge advancements in non-opioid medications by delving into their mechanisms of action at a molecular scale, scrutinizing results from current clinical research initiatives, and appraising preparedness for and plausibility of regulatory approval. The considerations aim to highlight how these treatments may offer viable...

This study analyzes the emergence of engineered antibody therapeutics for cancer, examining the factors driving their adoption. The limitations of monoclonal antibodies have led to an increasing demand for novel formats. Companies are developing multispecific antibodies, such as bispecifics and trispecifics, and antibody fragments, such as Fab and ...

Despite the term patient centricity gaining currency in the industry, there is a degree of variability in a companies’ approach and strategic priorities. Frost & Sullivan sees digitization playing a critical role in transforming the clinical trial model from traditional, high-cost, and difficult-to-access centralized settings to more patient-centri...

Pharmaceutical drug discovery and development suffers from declining success rates with new molecules and the rate of return shrinking from 16Percentage in 2011 to almost 11Percentage in 2018. Frost & Sullivan research indicates that traditional solutions that have focused primarily on data from limited sources and rule-based computational techniqu...